Motif Neurotech secures FDA IDE to initiate depression implant study
Summary
Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.
Description
Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source